FindTrial
Sign In

Phase 3 clinical study of MRA in patients with systemic juvenile idiopathic arthritis (sJIA)

Phase 3 clinical study of MRA in patients with systemic juvenile idiopathic arthritis (sJIA)

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220017
Enrollment
Unknown
Registered
2005-09-02
Start date
2005-09-02
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sJIA

Interventions

investigational material(s) Generic name etc : MRA (tocilizumab) INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for In

Sponsors

Chugai Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion criteria 1. Patients with sJIA diagnosed according to the revised 1997 ILAR (the International league of associations for Rheumatology) criteria 2. 2 and over Age and below 20

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
[Open label phase] Efficacy: JIA core set improvement. [Double blind phase] Efficacy: The main efficacy endpoint in the double blind withdrawal phase is the portion of patients maintaining JIA core set improvement. Safety: Frequency and severity of adverse events and adverse drug reactions—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026